Severe sepsis and
septic shock are important causes of death in intensive care units. Although Gram-negative
infections were predominant in the 1960s, Gram-positive
infections have increased in the past two decades and now account for about half of the cases of
severe sepsis. In this study, we examined the effect of a
Limulus anti-LPS factor (LALF)-derived
peptide on lung and liver Th1/Th2
cytokine mRNA levels during a Gram-positive
sepsis. We also examined the morphopathological changes observed in these organs during the disease. Mice challenged with a high dose of Staphylococcus haemolyticus showed severe damage in lung. In contrast, the liver of challenged mice showed an accumulation of bacterial particles in the sinusoids, associated with a severe inflammatory response due to high levels of tissue
mRNA proinflammatory
cytokines. Treatment with the
peptide LALF(32-51) ameliorated the
sepsis-induced effects in the lung and liver and increased the survival of mice in a dose- and time-dependent manner. Pretreatment with the
peptide LALF(32-51) differentially regulates
TNF-alpha, IFN-gamma,
IL-12p40,
IL-2 and
IL-10 mRNA levels in lung and liver of
peptide-treated mice, and limits the systemic inflammatory response. These findings support for the first time the effectiveness of an LALF-derived
peptide in the treatment of a Gram-positive
sepsis. Modulation of the Th1/Th2 pattern in tissues relevant for
sepsis correlates with an improved outcome of the disease as denoted by increased survival.